SynthesisFrontiers in cellular and infection microbiology2026
Artesunate repurposing for cytomegalovirus management: a systematic review of efficacy, mechanisms, and perspectives.
Synthesis in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytomegalovirus (CMV) is a prevalent opportunistic pathogen associated with significant morbidity and mortality in immunocompromised individuals, particularly transplant recipients and neonates. Current antiviral therapies are often constrained by substantial toxicity and the emergence of drug resistance. Artesunate (ART), a proven antimalarial agent with established safety profiles, has been explored for potential repurposing against CMV infection, though its anti-CMV pharmacodynamics remain incompletely elucidated. Methods: This systematic review synthesized evidence from 46 studies published through December 2025, covering Results: ART exhibits potent anti-CMV activity Conclusions: The short plasma half-life of ART may represent a pharmacokinetic limitation to its clinical application. Further research, including formulation optimization, targeted pharmacokinetic/pharmacodynamic studies, and well-controlled clinical trials, is warranted to evaluate the potential role of ART in CMV management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.